Loading…
Swiss biopharma developing and selling small-molecule drugs, including its insomnia treatment Quviviq (daridorexant).
Swiss biopharma developing and selling small-molecule drugs, including its insomnia treatment Quviviq (daridorexant).
Formed in 2017 when Actelion, bought by Johnson & Johnson, spun its drug-discovery arm into a new company led by its founders. Earns from its own launches of Quviviq in the US and Europe plus licence fees and milestones from partners, such as Viatris for two late-stage drugs, and has had to restructure its debt.
In one line: A smaller, cash-strapped Swiss Vertex Pharmaceuticals.
Moat: narrow (IP / patents). Patent-protected molecules, but reliant on continued launches amid a heavy debt load.
Headquarters: Allschwil, Switzerland · Founded: 2017 · Employees: 487
Size Idorsia (IDIA.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $1.34B, the 112th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 4.06 on 6 Nov 2026.
Performance Over six months the shares fell 5.0%, against -12.3% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 5.3% over the last twelve months (peer median +17.6%); the operating margin is -69.7% (peer median 2.9%).
Valuation It trades at 10.7× enterprise value to sales against a peer median of 6.9× (6th most expensive of 17).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 220M | CHF 221M | CHF 113M | CHF 152M | CHF 97.1M |
| Revenue growth | — | +96% | -26% | +57% | — |
| Gross profit | CHF 163M | CHF 182M | CHF 58.7M | CHF 126M | CHF 71.0M |
| EBITDA | -CHF 138M | -CHF 114M | -CHF 326M | -CHF 524M | -CHF 783M |
| Net income | -CHF 284M | -CHF 112M | -CHF 264M | -CHF 298M | -CHF 828M |
| Free cash flow | -CHF 114M | -CHF 169M | -CHF 373M | -CHF 638M | -CHF 876M |
| Capital expenditure | CHF 9.43M | CHF 13.8M | CHF 18.0M | CHF 9.40M | CHF 27.1M |
| Total debt | CHF 1.35B | CHF 1.29B | CHF 1.26B | CHF 1.20B | CHF 1.23B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Idorsia IDIA.SW | $1.34B | -5% | -5% | -70% | 10.7× | n/a |
| Vertex Pharmaceuticals VRTX | $139B | +27% | +11% | 35% | 10.7× | 6.1% |
| Jazz Pharmaceuticals Public JAZZ | $15.1B | +4% | +13% | 25% | 3.8× | -3.9% |
| Roche RO.SW | $385B | +22% | -1% | 31% | 5.6× | 0.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IDIA.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | -7.5% | 6th highest of 21 |
| 6-month return | -5.0% | -12.3% | 6th highest of 21 |
| Distance from 52-week high | -46.3% | -36.2% | 6th lowest of 21 |
| Revenue growth (TTM) | -5.3% | +17.6% | 3rd lowest of 17 |
| Operating margin | -69.7% | 2.9% | 5th lowest of 17 |
| EV / Sales | 10.7× | 6.9× | 6th most expensive of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | 10.7× | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 3.4× | -2.4% | +13.8% |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 2.1× | 0.3% | -1.3% |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | 11.2× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | 10.0× | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 1.4× | -7.4% | +12.7% |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 9.8× | 26.1% | +23.1% |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 2.0× | 8.5% | -5.3% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 0.5× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 5.0× | 4.0% | +27.9% |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | 417.6× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | 15.3× | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 2.4× | -15.4% | +3.9% |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | 15.5× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | 4.9× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | 617.6× | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 8.9× | n/a | n/a |